Previous close | 10.27 |
Open | 13.80 |
Bid | 14.02 x 100 |
Ask | 14.21 x 400 |
Day's range | 13.11 - 15.20 |
52-week range | 9.93 - 32.00 |
Volume | |
Avg. volume | 416,139 |
Market cap | 815.317M |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | 14.75 |
EPS (TTM) | 0.96 |
Earnings date | 09 May 2024 |
Forward dividend & yield | 0.60 (5.84%) |
Ex-dividend date | 27 Feb 2024 |
1y target est | 16.50 |
PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2024. "Our performance in the second quarter and fiscal first half of 2024 underscores the resiliency of our base business, as well as strong operational execution by our global team. Since our spinoff approximately two years ago, we've remained steadfast in delivering on
PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 14, 2024 to stockholders of record at the close of business on May 28, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live th
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...